On May 6, Professor Erika Lietzan presented her most recent paper at Stanford Law School, as part of its Law and the Biosciences Workshop. Her paper, Access Before Evidence and the Price of FDA’s New Drug Authorities, explores the costs of error and delay associated with federal government approval of new drugs, as well as costs associated with other less-studied aspects of…
Tag: Drug and Device Regulation ⋅ Page 1
Professor Lietzan Publishes Essay on Supreme Court Decision in Sandoz v. Amgen
This heavily-anticipated decision related to patent disputes between the developers of new biological medicines and the manufacturers of “biosimilar” copies of those medicines.
Professor Lietzan Named Affiliate Scholar of Center for the Protection of Intellectual Property
Professor Erika Lietzan has been named an Affiliate Scholar at the Center for the Protection of Intellectual Property, part of George Mason University’s Antonin Scalia Law School. She is also currently the recipient of an Thomas Edison Innovation Fellowship and a Leonardo da Vinci Fellowship Grant, both from the center, for a large historical and empirical project relating to restoration…